Determining the Bona Fide Nature of Fee-for-Service Arrangements
|
|
- Evan Simmons
- 8 years ago
- Views:
Transcription
1 Determining the Bona Fide Nature of Fee-for-Service Arrangements Mark DeWyngaert, PhD, MBA John Moose, MBA, CPA, ABV Elizabeth Gluck, Esq. September 27, 2012
2 About the Speakers Elizabeth Gluck, King & Spalding Elizabeth s practice focuses on drug price reporting issues related to the Medicaid, Medicare, Veterans Affairs, Federal Supply Schedule, 340B Drug Pricing, and related programs. She has assisted in multiple comprehensive assessments of pharmaceutical manufacturer price reporting and calculation practices and in the development and implementation of government price calculations and reporting policies, procedures, systems, and methodologies. Mark DeWyngaert, Huron Life Sciences mdewyngaert@huronconsultinggroup.com Mark DeWyngaert has provided operational, clinical, managerial, consulting, and litigation services to various segments of the health care industry. Mark trained as a molecular biologist and has been actively involved in both research and business development roles for the past 25 years. He specializes in assisting pharmaceutical manufacturers, biotechnology, and medical device companies with identifying and mitigating regulatory risks and valuing intellectual property. John Moose, Huron Life Sciences jmoose@huronconsultinggroup.com John specializes in providing valuation and market price related analyses for regulatory, financial reporting, and litigation purposes. He is an expert in assessing the fair market value of services provided under fee-for-service arrangements. John holds a MBA from the University of Michigan, and is a CPA and accredited in business valuation by the AICPA. He has applied complex accounting literature to the valuation of numerous intangible assets, including trademarks, developed technology, in-process research and development, non-compete agreements, and assembled workforce. 2
3 Disclaimer This presentation contains general information only. The presenters are not, by means of this presentation, rendering accounting, legal, or other professional advice or services. The opinions expressed herein are solely those of the presenter(s) and do not represent the opinions or policies of their employers or clients. 3
4 Agenda Bona Fide Service Fees Assessing Fair Market Value FMV and the Contracting Process Example Service Fee Analysis Questions and Answers 4
5 Bona Fide Service Fees Bona fide service fees ( BFSF ) are excluded from the calculations of Average Manufacturer Price ( AMP ) and Best Price. Not all service fees are bona fide. Service fees that are not bona fide are treated as price concessions and included in the calculations of AMP and Best Price. A service fee may only be considered bona fide, and thus excludable from AMP and Best Price, if it meets all of the criteria of the bona fide service fee exemption (the BFSF Test ). Certain wholesaler service fees are also excluded from Non-Federal Manufacturer Price ( Non-FAMP ), but the term BFSF is strictly a CMS construction. 5
6 Bona Fide Service Fees Patient Protection and Affordable Care Act of 2010 ( PPACA ) Congress for the first time articulated several services that could be considered bona fide. AMP excludable BFSF could include, but are not limited to: Distribution service fees; Inventory management fees; Product stocking allowances; and Fees associated with administrative service agreements and patient care programs (such as medication compliance programs and patient education programs). 1 6
7 Bona Fide Service Fees In November of 2010, CMS issued a final rule withdrawing and amending regulations that had governed the calculations of AMP and Best Price since October 1, CMS wrote that the definition of BFSF should not be used in the calculation of AMP. However, it is still to be used for Best Price. 3 Statutory reference 4 to BFSF is not a definition. How to define BFSF in AMP pending publication of the final AMP regulation? Guidance in 2012 AMP proposed rule; and Manufacturer s reasonable assumptions. 7
8 Bona Fide Service Fees Proposed AMP Regulation (February 2012): References the specific service fees cited in the statute, but suggests these fees must meet the existing regulatory criteria for BFSF to qualify as excludable. Limits the types of entities that may be paid excludable BFSF to wholesalers, retail community pharmacies, or any other entity that conducts business as a wholesaler or a retail community pharmacy. 5 8
9 Bona Fide Service Fees Proposed AMP Regulation (February 2012): Group Purchasing Organization ( GPO ) administrative fees may also be eligible for exclusion, provided they satisfy all other elements of the BFSF Test. Price Appreciation Credits (which CMS characterized as retroactive price adjustments ) never considered BFSF. 6 9
10 Bona Fide Service Fees Proposed AMP Regulation (February 2012): Consistent with prior practice, CMS declined to define Fair Market Value ( FMV ). CMS indicated in the preamble that it believes, that manufacturers should appropriately determine fair market value and make reasonable assumptions consistent with adequate documentation that will support their payment for these services at fair market rates sufficient that an outside party can determine the basis for the fair market value determination. 7 This language suggests that formal documentation of FMV analyses is now expected by CMS. 10
11 Bona Fide Service Fees Goals in Assessing Potentially Bona Fide Services Your company should assess potentially bona fide services to: Respond to CIA or DPA requirements; Adhere to OIG guidance; Mitigate risk of overpaying and creating perception of an improper payment; Facilitate additional oversight during contract evaluation to allow for consistency across contracts; Provide business partners with the justifiable means for communicating payment amounts to vendors and other third parties; and Support adherence to company policy. 11
12 Bona Fide Service Fees Questions to ask Many companies are working with outside vendors to address several questions raised by the guidance in the proposed AMP regulation including: Which of the services under fee-for-service arrangements should be considered bona fide? Are payments for bona fide services treated properly in my government pricing calculations? Are my contracts clearly delineating the bona fide services received? Are my contracts clearly linking FMV fees to the bona fide services provided for under the contract? Has my company adequately calculated and documented fair market value? 12
13 Bona Fide Services Bona Fide Service Fee Test Under the proposed AMP Rule, to be considered bona fide a service fee must satisfy each the following four criteria: The fee paid must be for a bona fide, itemized service that is actually performed on behalf of the manufacturer; The manufacturer would otherwise perform or contract for the service in the absence of the service arrangement; The fee represents FMV for the services rendered; and The fee is not passed on in whole or in part to a client or customer of any entity. 13
14 Bona Fide Service Fees Key Treatment of Bona Fide Service Fees Proper treatment of fees paid to service providers is critical to ensure the accuracy of GP statutory pricing calculations and integrity of prices reported to the government. One of the most important aspects of BFSF and FMV evaluation is the rationale and documentation required in order to demonstrate due diligence in the decision making process. In this dynamic regulatory environment, and given the evolving guidance, it is critical to have a clear record of the rationale for your determinations The scrutiny on BFSF s has increased dramatically, as they are determinations that must be made by the manufacturer, and can have a dramatic impact on reported government prices Manufacturers cannot make determinations based upon what is conservative or aggressive as the impact of calling a payment a Bona Fide Fee for Service and exempt from calculations can be conservative in one program and aggressive in another 14
15 Bona Fide Service Fees Examples of Potentially Bona Fide Services Examples of potentially bona fide services are provided below. This is not meant to be an exhaustive list. GPOs, MCOs, and PBMs Specialty Pharmacy Wholesalers and Distributors Maintain customer lists; Notify customers of changes in contract prices or terms; Data reporting sales and market share; Program oversight and contract consulting; Audit wholesaler data; Resolve billing, chargeback, and rebate issues; Provide members with contract modeling tool; Conduct contract modeling for member on manufacturer s behalf; Provide promotional activities such as blasts and webcasts; Exhibits and meeting attendance; Sponsorships; Focus groups/ad boards; Speaker programs; and Market research. Coordination with company s call center hub; Custom scripted calls to patients; High-risk patient assessments; Sending promotional or educational materials; Express shipping; Call center; Complex benefits investigation; Sales and inventory reporting; and Product replacement services. Inventory management (Primarily Branded); Customer service levels (Branded and Generic); Information and data service fees (Branded and Generic); Indirect Contract Administration (Branded and Generic); and Range of services associated with generic introduction (Generic): o Marketing materials; o Rapid product introduction; o Promotional events; and o Distribution of free product. 15
16 Bona Fide Service Fees Developing a Robust Compliance Program Develop policies and procedures governing the assessment of whether fees paid to service providers are Bona Fide. Ensure company has a pricing committee. Ensure distribution and commercial contracting groups are actively communicating contracting plans early on in the process. Perform a thorough BFSF evaluation and FMV analysis, documenting rationale, and assumptions. Document treatment of service fees in statutory pricing calculations. Ensure analysis and application of fees are reviewed; Involvement from internal/external counsel; and Consider utilizing external consultants (SME) for FMV analysis. 16
17 Bona Fide Service Fees Next Steps Branded and generic pharmaceutical manufacturers should consider: Reviewing current contracts to: Assess consistency in payments within and between contracts; Determine if all the fees paid to service providers (e.g., in exchange for services or data) that are treated as Bona Fide in statutory price calculations are itemized in the contract and properly linked to payment; and Identify clauses that allow for adjustment of payment or no payment if bona fide services or data is not received or provided as contracted. Preparing a business case to document business need for services; Calculating and documenting fair market value of service or data requests; Assessing whether bona fide service fees are properly treated in government pricing calculations; and Establishing internal controls to verify and document receipt of service(s) and data. 17
18 Assessing Fair Market Value 18
19 Assessing Fair Market Value Fair Market Value Defined A fair market value definition generally accepted in the valuation industry: The price, expressed in terms of cash equivalents, at which property would change hands between a hypothetical willing and able buyer and a hypothetical willing and able seller, acting at arm s length in an open and unrestricted market, when neither is under compulsion to buy or sell and when both have reasonable knowledge of the relevant facts. (1) [emphasis added] 1. American Society of Appraisers Business Valuation Standards Glossary ; Approved June 2005 Copyright 2005, American Society of Appraisers 19
20 Assessing Fair Market Value Steps to Assessing Fair Market Value Identify and define the potentially bona fide services to be valued; Understand the market(s) for that service; Determine controls used to validate receipt of service; Determine methodologies to be applied; Apply the methodologies; Implement at the service level; and Implement at the contract level, if applicable. 20
21 Assessing Fair Market Value Identify and define potentially bona fide services Identify potential fee-for-service arrangements through interviews and a comprehensive review or sampling of contracts. Review the fee-for-service arrangements for potentially bona fide services. Every bona fide service or data set should be clearly defined. Description; Attributes that may drive value; and The primary tangible and intangible assets employed to deliver the service or data set (which drives the level of reasonable profit). 21
22 Assessing Fair Market Value Levels of FMV The manufacturer must determine at what level the FMV assessment will be determined: Activity (e.g., call, educational insert, letter) Service (e.g., activity times volume for the contract) Contract (e.g., fair market value for all services in a contract) 22
23 Assessing Fair Market Value Understand the market for the service Attributes of the market to be considered may include: Pricing Efficiency; Bargaining power of buyer and seller (e.g., market share); Buyer and seller knowledge of other transaction prices; and Access to unique assets (e.g., customer relationships). A solid understanding of the markets in which services are bought and sold will allow for a more accurate assessment of the profit to be placed on the service or data set. 23
24 Assessing Fair Market Value Valuation Approaches Generally accepted valuation principles employ three primary approaches to value: 24
25 Assessing Fair Market Value Valuation Methodologies Strengths and Weaknesses Each method has advantages and disadvantages for any given service or data set. Income Approach Requires significant number of assumptions or effort in data gathering but may be the most flexible valuation methodology. Market Approach No two services are exactly alike or exchanged under the same circumstances; and Adjustments for specific differences in value drivers between the observed prices and the subject prices may be difficult or impossible. Specific knowledge of all value drivers is usually not provided in the contract and the circumstances surrounding negotiation of the contract are usually not available. Cost Approach Results may lack a connection to observed prices; Certain estimates are required but the estimates have the potential to provide a more accurate estimate than that provided by the Market Approach; and Cost drivers are apparent which allows for a better educated buyer of the services. 25
26 Assessing Fair Market Value What s in a Price? Price for a bona fide service can be thought of as an amount that covers: The direct cost of the service; The overhead associated with delivering that service; The cost of assets used up in the delivery of the service; and A reasonable return on the assets employed in the delivery of that service. These four factors may not always be appropriate in assessing fair market value in all cases. 26
27 Assessing Fair Market Value Conclusion Your conclusion of fair market value should consider the results of all methods employed, but may rely entirely on one method. The fair market value should be a range, not a point estimate. Once a fair market value range for an activity is determined, the amount should be multiplied by the volume of that activity for each type of service and added together to arrive at a fair market value range for the contract. 27
28 Assessing Fair Market Value Attributes to Consider Fair market value assessments for fees paid to service providers determined to be Bona Fide should be: Documented Defensible Consistent Flexible 28
29 FMV and the Contracting Process 29
30 FMV and the Contracting Process Consider adding an FMV review to the Contracting Committee analysis. - Diversity in representation on the Committee helps to ensure that practical considerations are not overlooked. Implement an SOP to detail when and how to apply FMV. - An SOP demonstrates an organization s commitment to any reviewing agency. o Include a formal exceptions process; o Train on the SOP; and o Audit against the SOP. Develop a template contract with the assistance of legal counsel. 30
31 FMV and the Contracting Process Perform a thorough FMV analysis of current services, documenting rationale and assumptions. Empower employees to gain acceptance. Clarify importance of FMV implications for statutory price calculations and contracting process; Explain the policy and how rates were derived; and Encourage employees to negotiate rates within the FMV ranges. 31
32 Example Service Fee Analysis 32
33 Example Service Fee Analysis New and Enrolled Patient Support Patient support services for product adherence program are designed to address the unique characteristics of patients and may require specialized skills of healthcare professionals familiar with multi-faceted treatment regimens and causes for patients not adhering or dropping off of therapy. An example of a fair market value analysis of a call to a patient follows: 33
34 Questions Mark DeWyngaert Huron Life Sciences P mdewyngaert@huronconsultinggroup.com John Moose Huron Life Sciences P jmoose@huronconsultinggroup.com Elizabeth Gluck King & Spalding P egluck@kslaw.com 34
35 Endnotes 1 [42 U.S.C. Section 1396-r8(k)(1)(B)(i)(II)] 2 [75 Fed. Reg. at 69,591 (November 15, 2010)] 3 [75 Fed. Reg. at 69,593] 4 [42 U.S.C. Section 1396-r8(k)(1)(B)(i)(II)] 5 [77 Fed. Reg. at 5321, 5327, 5332 (Feb. 2, 2012); proposed sections , (c)(14), and (c)(16) 6 [77 Fed. Reg. at 5332] 7 [77 Fed. Reg. at 5332] 35
36 Thank you for your participation.
340B Drug Discount Program Overview and Emerging Issues
340B Drug Discount Program Overview and Emerging Issues I. APPLICABLE STATUTE AND OTHER LEGAL AUTHORITIES Section 340B of the Public Health Service Act (42 U.S.C. 256b) requires pharmaceutical manufacturers,
More informationHCCA 2013 COMPLIANCE INSTITUTE ANTI-KICKBACK STATUTE 101 SEATTLE, WASHINGTON
UW MEDICINE HCAA 2013 Compliance Institute HCCA 2013 COMPLIANCE INSTITUTE ANTI-KICKBACK STATUTE 101 April 23, 2013 Robert S. Brown Senior Compliance Specialist UW Medicine Compliance SEATTLE, WASHINGTON
More informationE-ALERT Health Care HEALTH CARE REFORM: MEDICAID PRESCRIPTION DRUG REIMBURSEMENT. Executive Summary
E-ALERT Health Care April 2010 HEALTH CARE REFORM: MEDICAID PRESCRIPTION DRUG REIMBURSEMENT On March 23, 2010, President Obama signed into law Pub. L. No. 111-148, the Patient Protection and Affordable
More informationFair Market Value and Payments to Healthcare Professionals How Should We Determine What We Pay? Huron Consulting Services LLC. All rights reserved.
Fair Market Value and Payments to Healthcare Professionals How Should We Determine What We Pay? Huron Consulting Services LLC. All rights reserved. Contact Information Debjit Ghosh Life Sciences Practices
More informationValuation of Physician Practices
Valuation of Physician Practices Presentation Summary! Overview! As mergers and acquisitions of physician practices continue to be prevalent, an understanding of valuation and relevant compliance considerations
More informationPhysician Practice Valuation: Key Concepts to Ensure Compliant Physician Practice Acquisitions. Presented by: Stuart A. Neiberg, MAcc, CPA, CFA
: Key Concepts to Ensure Compliant Physician Practice Acquisitions Presented by: Stuart A. Neiberg, MAcc, CPA, CFA Physician Practice Acquisition Overview Significant Consolidation / Acquisition Activity
More informationXXXXXXXFUNDAMENTALS An Essential Guide for Health System Executive Management
340B XXXXXXXFUNDAMENTALS An Essential Guide for Health System Executive Management 800.473.3516 www.wellpartner.com Table of Contents 340B Fundamentals for Health System Executive Management...1 What
More informationEstablishing Fair Market Value under the Anti-kickback and Stark Laws
Establishing Fair Market Value under the Anti-kickback and Stark Laws Katherine A. Lauer, Partner Latham & Watkins LLP San Diego, CA Framingham, MA www.cpa.net Overview Legal Issues Regulatory Guidance
More informationPrescription-drug expenditures are one of
Effective Contracting with Pharmacy Benefit Managers: Protecting a plan sponsor s resources by Brian N. Anderson and Robert Cosway 20% 19% 18% 17% 16% 15% 14% 13% 12% 11% 10% 9% 8% 7% 6% 5% 4% 3% 2% 1%
More information3. HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION
1. PURPOSE It is the goal of UCB, Inc. (UCB) to ensure that its marketing and promotional activities comply with all applicable state and federal laws. In addition, UCB Inc. endeavors to conform to pertinent
More informationStatement of the Biotechnology Industry Organization Before the Advisory Panel on Ambulatory Payment Classification Groups August 23-24, 2010
Statement of the Biotechnology Industry Organization Before the Advisory Panel on Ambulatory Payment Classification Groups August 23-24, 2010 Laurel Todd Director, Reimbursement and Health Policy Biotechnology
More informationA client guide to business valuation engagements and reports.
A client guide to business valuation engagements and reports. Disclaimer This guide is distributed with the understanding that the author, publisher and distributor are not rendering legal, accounting
More informationSpeakers. Recent Developments in 340B Drug Pricing Program Compliance and Enforcement. Elizabeth S. Elson, Esq. Anil Shankar, Esq.
1 Recent Developments in 340B Drug Pricing Program Compliance and Enforcement Elizabeth S. Elson, Esq. Anil Shankar, Esq. October 18, 2012 2 Speakers Elizabeth Elson Of Counsel Foley & Lardner LLP Los
More informationChapter 4: Buying an Existing Business
Chapter 4: Buying an Existing Business 1 Learning Objectives To understand that buying an existing business has several important advantages over starting one, including less risk, less time and effort,
More informationA fter much-anticipation, the Health Resources and
BNA s Health Care Policy Report Reproduced with permission from BNA s Health Care Policy Report, 23 HCPR 1420, 09/21/2015. Copyright 2015 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com
More informationKeep Your Savings: 340B Audits and Ensuring Compliance
Keep Your Savings: 340B Audits and Ensuring Compliance Disclosure This presentation reflects experience with the topics at hand and does not constitute legal advice, and does not reflect interpretation
More informationMedical Care Advisory Committee. Andy Vasquez, Deputy Director, Medicaid/CHIP Vendor Drug Program Health and Human Services Commission
TO: Medical Care Advisory Committee DATE: November 8, 2013 FROM: Andy Vasquez, Deputy Director, Medicaid/CHIP Vendor Drug Program Health and Human Services Commission Agenda Item No.: 7 SUBJECT: Fee-for-Service
More informationThe Future of Consumer Health Care
The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More
More informationSMALL BUSINESS DEVELOPMENT CENTER RM. 032
SMALL BUSINESS DEVELOPMENT CENTER RM. 032 THE BUSINESS VALUATION PROCESS: BUYING/SELLING A BUSINESS (c) Revised January, 2013 Board of Regents, University of Wisconsin System Julie Britz, Writer; Mark
More informationO n Aug. 28, the Department of Health and Human
BNA s Health Law Reporter Reproduced with permission from BNA s Health Law Reporter, 24 HLR 1202, 9/17/15. Copyright 2015 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com HRSA
More informationFollowing is a restatement of the primary duties of the six paralegals you describe:
December 16, 2005 FLSA2005-54 Dear Name* : This is in response to your request for a formal opinion on the application of Section 13(a)(1) of the Fair Labor Standards Act (FLSA) to several paralegals employed
More information340B Drug Pricing Program. A Survey of the Program s Past, Present, and Future
340B Drug Pricing Program A Survey of the Program s Past, Present, and Future Presented by: Daniel Soldato Wyatt, Tarrant & Combs LLP dsoldato@wyattfirm.com (859) 288-7631 Disclaimer The views expressed
More informationMEDICAID DRUG PRICE COMPARISON: AVERAGE SALES PRICE TO AVERAGE WHOLESALE PRICE
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL MEDICAID DRUG PRICE COMPARISON: AVERAGE SALES PRICE TO AVERAGE WHOLESALE PRICE Daniel R. Levinson Inspector General June 2005 OEI-03-05-00200
More informationIntroduction. Plan sponsors include employers, unions, trust funds, associations and government agencies, and are also referred to as payors.
Maintaining the Affordability of the Prescription Drug Benefit: How Managed Care Organizations Secure Price Concessions from Pharmaceutical Manufacturers Introduction The purpose of this paper is to explain
More informationJuly 27, 2015. Dear Acting Administrator Slavitt:
Acting Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-2390-P P.O. Box 8106 Baltimore, MD 21244-8016 Re: Proposed Rule for Medicaid and Children
More informationUPDATED. Special Advisory Bulletin on the Effect of Exclusion from Participation in Federal Health Care Programs
UPDATED Special Advisory Bulletin on the Effect of Exclusion from Participation in Federal Health Care Programs Issued May 8, 2013 Updated Special Advisory Bulletin on the Effect of Exclusion from Participation
More informationWHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain
WHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing
More informationFinally... maybe? The Long Awaited 340B Mega Guidance. Georgia Healthcare Financial Management Association. October 2015
Finally... maybe? The Long Awaited 340B Mega Guidance Georgia Healthcare Financial Management Association October 2015 Disclaimer This webinar assumes the participant is familiar with the basic operations
More informationIN PRINT. Keri Tonn. 1 73 Fed. Reg. 56832 (Sept. 30, 2008). 2 65 Fed. Reg. 14289 (Mar. 16, 2000).
IN PRINT OIG s Supplemental Compliance Program Guidance for Nursing Facilities Keri Tonn On September 30, 2008, the Office of the Inspector General of the Department of Health and Human Services (OIG)
More information340B program presents opportunities and challenges
NOVEMBER 2009 healthcare financial management MEDICARE/MEDICAID Christopher L. Keough Stephanie A. Webster 340B program presents opportunities and challenges AT A GLANCE > The 340B program provides an
More information340B Mega Guidance: Implications for Essential Hospitals Sarah Mutinsky and Barbara Eyman Washington Counsel, America s Essential Hospitals Eyman
340B Mega Guidance: Implications for Essential Hospitals Sarah Mutinsky and Barbara Eyman Washington Counsel, America s Essential Hospitals Eyman Associates September 10, 2015 TODAY S AGENDA Background
More informationCMSS Physician Payment Sunshine Act FAQs
CMSS Physician Payment Sunshine Act FAQs These FAQs are intended as a resource for CMSS member organizations to create their own guidance document. The answers are based on the guidance that is publicly
More informationLegal Alert. Long-Awaited 340B Program Guidance Now Available for Comments: What Stakeholders Need to Know. Authors
September 10, 2015 1 Legal Alert Authors Stephanie Trunk Partner stephanie.trunk@arentfox.com Erin E. Atkins Associate erin.atkins@arentfox.com Long-Awaited 340B Program Guidance Now Available for Comments:
More information(RIN) 0906-AB08; 340-B
October, 2015 Ms. Krista Pedley Director, Office of Pharmacy Affairs (OPA) Health Resources and Services Administration (HRSA) 5600 Fishers Lane, Mail Stop 08W05A Rockville, Maryland 20857 Re: Regulatory
More informationMinimizing Working Capital Disputes in Healthcare Deals
April 2014 Minimizing Working Capital Disputes in Healthcare Deals By: Ken Conner, CPA Shannon Farr, CPA/ABV/CFF Cole Powell, CPA/CGMA/FHFMA Working Capital Settlement Woes Too often, a game of tug of
More informationNACHC ANALYSIS: Establishing and Collecting Fees for Health Center Services. July, 2009
NACHC ANALYSIS: Establishing and Collecting Fees for Health Center Services July, 2009 Prepared for NACHC by: Michael Glomb Feldesman, Tucker, Leifer, Fidell 2001 L Street, N.W. (202)466-8960 mglomb@feldesmantucker.com
More informationOIG Provides Guidance on Internet Advertising Under the Anti-Kickback Law
NUMBER 230 FROM THE LATHAM & WATKINS HEALTH CARE PRACTICE GROUP BULLETIN NO. 230 OCTOBER 25, 2002 OIG Provides Guidance on Internet Advertising Under the Anti-Kickback Law This Advisory Opinion offers
More informationAUDIT OF CAPITAL CITY TRADE AND TECHNICAL SCHOOL, INC. COMPLIANCE WITH THE 85 PERCENT RULE
AUDIT OF CAPITAL CITY TRADE AND TECHNICAL SCHOOL, INC. COMPLIANCE WITH THE 85 PERCENT RULE FINAL AUDIT REPORT Control Number ED-OIG/A06-80008 February 2000 Our mission is to promote the efficient and effective
More informationPatient Protection & Affordable Care Act Understanding Management Liability Exposures Created by the PPACA
Patient Protection & Affordable Care Act Understanding Management Liability Exposures Created by the PPACA May 7, 2015 Christopher Williams Travelers About PLUS PLUS is a nonprofit organization that provides
More informationBrief Summary of the National Physician Payment Transparency Program: Open Payments Physician Payment Sunshine Act
Brief Summary of the National Physician Payment Transparency Program: Open Payments Physician Payment Sunshine Act (Prepared by the Department of Health Policy and Regulatory Affairs, February 26, 2013)
More informationCALCULATION OF VOLUME- WEIGHTED AVERAGE SALES PRICE FOR MEDICARE PART B PRESCRIPTION DRUGS
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL CALCULATION OF VOLUME- WEIGHTED AVERAGE SALES PRICE FOR MEDICARE PART B PRESCRIPTION DRUGS Daniel R. Levinson Inspector General February
More informationFocus on Pharmacy Management PHYSICIAN DISPENSING
PHYSICIAN DISPENSING 1 Introduction The National Council on Compensation Insurance (NCCI), the largest provider of workers compensation and employee injury data and statistics in the nation, released a
More information340B Drug Pricing Program
340B Drug Pricing Program Chad E. Gay Director of Contract Compliance Agenda Discuss the 340B drug pricing program How the program is defined Who is eligible Enrollment Dates to be aware of Source Documentation
More informationCMS Publishes Final Rule Regarding Medicaid Drug Rebate Program
CMS Publishes Final Rule Regarding Medicaid Drug Rebate Program February 1, 2016 Health Care Today, the Centers for Medicare & Medicaid Services (CMS) published in the Federal Register the long-awaited
More informationDivision of Swap Dealer and Intermediary Oversight
U.S. COMMODITY FUTURES TRADING COMMISSION Three Lafayette Centre 1155 21st Street, NW, Washington, DC 20581 Telephone: (202) 418-6700 Facsimile: (202) 418-5528 gbarnett@cftc.gov Division of Swap Dealer
More informationREALIZING VALUE - BUYING AND SELLING YOUR BUSINESS
REALIZING VALUE - BUYING AND SELLING YOUR BUSINESS Presented By: Norm Snyder and Jeff Capron November 2009 805 King Farm Boulevard, Suite 300 Rockville, Maryland 20850 301.231.6200 301.231.7630 F www.aronsoncompany.com
More informationMinimizing Working Capital Disputes in Healthcare Deals
Minimizing Working Capital Disputes in Healthcare Deals By Ken Conner, CPA, Shannon Farr, CPA ABV CFF and Cole Powell, CPA, CGMA, FHFMA Published April 16, 2013 A global reach with a local perspective.
More informationA Closer Look at Purchase Price Allocations
A Closer Look at Purchase Price Allocations Companies making acquisitions must comply with the Fair Value accounting rules of ASC 805, Business Combinations, and should consider an independent valuation
More informationNatalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services. CVS Caremark Corporation
Prepared Statement of Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services CVS Caremark Corporation Before the Subcommittee on Regulatory Reform, Commercial and Antitrust
More informationPRICE REPORTING COMPLIANCE: BEST PRACTICES IN REPORTING MEDICAID DRUG REBATE PROGRAM AND PART B ASP DATA. November 16, 2004
PRICE REPORTING COMPLIANCE: BEST PRACTICES IN REPORTING MEDICAID DRUG REBATE PROGRAM AND PART B ASP DATA November 16, 2004 Andrew Ruskin Vinson & Elkins LLP Washington, DC Medicaid Drug Rebate Program
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES. Medicare, Medicaid, Children's Health Insurance Programs; Transparency Reports
This document is scheduled to be published in the Federal Register on 02/08/2013 and available online at http://federalregister.gov/a/2013-02572, and on FDsys.gov 1 DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationEmptoris Contract Management Solution for Healthcare Providers
Emptoris Contract Management Solution for Healthcare Providers An Emptoris White Paper Emptoris, an IBM Company www.emptoris.com CMS-HP-4/12 Emptoris Contract Management Solution for Healthcare Providers
More informationFACTORS TO CONSIDER IN PERFORMING A VALUATION ANALYSIS FOR A FAIRNESS OPINION
Insights Winter 2009 58 Financial Adviser Insights FACTORS TO CONSIDER IN PERFORMING A VALUATION ANALYSIS FOR A FAIRNESS OPINION Craig A. Jacobson Valuation analyses are at the core of any fairness opinion
More information340B University Page 1 340B Manager and Coordinator Job Description Template
340B University Page 1 Purpose: The purpose of this tool is to provide a list of activities commonly assigned to the role of 340B Manager or Coordinator. This list is not exhaustive, rather a compilation
More informationNOTICE TO CLIENTS WHO CONTEMPLATE FILING BANKRUPTCY
NOTICE TO CLIENTS WHO CONTEMPLATE FILING BANKRUPTCY The purpose of this Notice and The Statement Mandated by Section 527(b) of the Bankruptcy Code, which you have been provided as a separate document are
More informationGROWTH OF THE 340B PROGRAM: PAST TRENDS, FUTURE PROJECTIONS
: PAST TRENDS, FUTURE PROJECTIONS Healthcare WHITE PAPER NOVEMBER 2014 Prepared By: Aaron Vandervelde avandervelde@thinkbrg.com 202.480.2661 Copyright 2014 by Berkeley Research Group, LLC. Except as may
More informationThe duties and the amount of time, in general, that an IT Support Specialist would spend on such duties are described below:
U.S. Department of Labor Employment Standards Administration Wage and Hour Division Washington, D.C. 20210 October 26, 2006 FLSA2006-42 Dear Name*: This is in response to your request for an opinion concerning
More information340B DISCOUNT DRUG PROGRAM OVERVIEW
340B DISCOUNT DRUG PROGRAM OVERVIEW March 2014 Investment banking services are provided by Harris Williams LLC, a registered broker-dealer and member of FINRA and SIPC, and Harris Williams & Co. Ltd, which
More informationA BILL. To provide a single, universal, comprehensive health insurance benefit for all residents of Illinois, and for other purposes.
Synopsis: This bill expands comprehensive health coverage to all Illinois residents using a single-payer statewide insurance system. Doctors and hospitals remain private, and patients retain their choice
More informationMedicare Coverage Gap Discount Program (Filling the Donut Hole)
Medicare Coverage Gap Discount Program (Filling the Donut Hole) Summary: Requires drug manufacturers to provide a 50 percent discount to Part D beneficiaries for brand name drugs and biologics purchased
More information340B and the Pharmacy Wholesaler s Role
340B and the Pharmacy Wholesaler s Role Daniel Neal Sr. Product/Market Mgr., 340B Innovative Delivery Solutions 10 th Annual 340B Coalition Winter Conference Wednesday, February 5, 2014 Disclaimer The
More informationTRADE AGREEMENTS ACT LIMITATIONS ON PROCUREMENT OF PHARMACEUTICALS AND POTENTIAL VA SOLUTIONS
TRADE AGREEMENTS ACT LIMITATIONS ON PROCUREMENT OF PHARMACEUTICALS AND POTENTIAL VA SOLUTIONS Donna Lee Yesner Morgan, Lewis & Bockius, LLP dyesner@morganlewis.com (202)739-5887 The Trade Agreements Act,
More informationGuide Note 11 Comparable Selection in a Declining Market
Guide Note 11 Comparable Selection in a Declining Market Introduction A declining market is generally characterized by few transactions and falling values. Declining markets present valuation challenges
More informationHospital Acquisition of Physician Practices
Hospital Acquisition of Physician Practices What is driving physician practice acquisitions? Reimbursement declines in certain specialties leading to decreased physician compensation Healthcare reform
More informationAmbulatory Surgery Centers: Valuation Process & Key Benchmarks
Ambulatory Surgery Centers: Valuation Process & Key Benchmarks Chance Sherer, CVA Director 1 PRESENTATION OVERVIEW I. Industry Background II. III. Valuations: When and Why Types of Transactions IV. Overview
More informationIntellectual Property Valuation Techniques
By Daryl Martin and David Drews* IPmetrics LLC INTRODUCTION Unlike many of the other assets found on a company s balance sheet, the intangible assets, such as patents, trademarks and copyrights, are among
More informationFUND MANAGER CODE OF CONDUCT
FUND MANAGER CODE OF CONDUCT First Edition pursuant to the Securities and Futures Ordinance (Cap. 571) April 2003 Securities and Futures Commission Hong Kong TABLE OF CONTENTS Page INTRODUCTION 1 I. ORGANISATION
More informationRETIREMENT INSIGHTS. Understanding your fiduciary role. A plan sponsor fiduciary guide
RETIREMENT INSIGHTS Understanding your fiduciary role A plan sponsor fiduciary guide ABOUT Perhaps no one topic in the employee benefits arena has drawn more attention and scrutiny over the last several
More informationSELLING OR BUYING A PRIVATE COUNSELING PRACTICE
American Counseling Association Dedicated to the growth and development of the counseling profession and those who are served Proudly serving the counseling community for over 50 years! 5999 Stevenson
More informationGAO DRUG PRICING. Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement
GAO United States Government Accountability Office Report to Congressional Committees September 2011 DRUG PRICING Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs
More informationCompliance Reporting and Auditing: Best Practice Exchange Tony Farino, Partner Peter Claude, Sr. Manager PricewaterhouseCoopers LLP November 14, 2002
Compliance Reporting and Auditing: Best Practice Exchange Tony Farino, Partner Peter Claude, Sr. Manager PricewaterhouseCoopers LLP November 14, 2002 Concurrent Session Agenda Compliance Auditing: Why
More informationGeneral Valuation Factors ERISA Counsel May Consider in an ESOP Litigation Case
Forensic Analysis Insights ESOPs and ERISA General Valuation Factors ERISA Counsel May Consider in an ESOP Litigation Case Chip Brown, CPA, and Steve Whittington As part of an ERISA litigation matter involving
More informationELECTRONIC PRESCRIBING
GAO United States Government Accountability Office Report to Congressional Committees February 2011 ELECTRONIC PRESCRIBING CMS Should Address Inconsistencies in Its Two Incentive Programs That Encourage
More informationOFFICE OF CHARITABLE AND REGULATORY PROGRAMS. Credit Services Businesses Frequently Asked Questions. Registration Requirements
OFFICE OF CHARITABLE AND REGULATORY PROGRAMS Credit Services Businesses Frequently Asked Questions Registration Requirements Credit Services Businesses in Virginia are required to register with the Office
More informationBucks County Community College Foundation Gift Acceptance Policy
Bucks County Community College Foundation Gift Acceptance Policy Introduction The Bucks County Community College Foundation (hereinafter referred to as the Foundation), a not-for-profit, independent 501(c)(3)
More informationThe Pharmacy 340B Program- Compliance & Internal Audit Strategies. for Covered Entities. Matthew D. Vogelien Huron Healthcare
The Pharmacy 340B Program- Compliance & Internal Audit Strategies Matthew D. Vogelien Huron Healthcare for Covered Entities 340B Drug Discount Program (340B Program) Discussion Outline Topics for Discussion:
More informationStructuring Physician Recruitment Arrangements in Accordance with the Stark II/Phase II Interim Final Rule
Structuring Physician Recruitment Arrangements in Accordance with the Stark II/Phase II Interim Final Rule Stacey A. Tovino satovino@central.uh.edu June 25, 2004 On March 26, 2004, the Centers for Medicare
More informationCommon issues surrounding non-cash contributions
Accepting Unique or Unusual Contributions By Laura J. Kenney and Nancy Murphy * It is not easy to say "thanks, but no thanks" to a donor. In some cases, however, "no thanks" may be the wisest answer for
More information340B Omnibus Guidance Would Significantly Narrow the Pool of Eligible Patients
White Paper August 31, 2015 340B Omnibus Guidance Would Significantly Narrow the Pool of Eligible Patients By Kristi V. Kung This client alert also was published as a bylined article on Law360 on September
More informationSUPPLEMENTAL NOTE ON SUBSTITUTE FOR SENATE BILL NO. 11
Corrected SESSION OF 2007 SUPPLEMENTAL NOTE ON SUBSTITUTE FOR SENATE BILL NO. 11 As Amended by House Committee of the W hole Brief* Sub. for SB 11, as amended by the House Committee of the Whole, would
More information340B Drug Pricing Program 340B Contract Pharmacy
340B Drug Pricing Program 340B Contract Pharmacy LTJG Enudio Mercado-Gonzalez, USPHS Program Management Officer U.S. Department of Health and Human Services Health Resources and Services Administration
More informationThis letter has been withdrawn. See Administrtor Interpretation 2010-1. September 8, 2006
U.S. Department of Labor Employment Standards Administration Wage and Hour Division Washington, D.C. 20210 This letter has been withdrawn. See Administrtor Interpretation 2010-1. September 8, 2006 FLSA2006-31
More informationUnderstanding the Key Challenges when Entering into a Corporate Integrity Agreement
Understanding the Key Challenges when Entering into a Corporate Integrity Agreement Understanding the Key Challenges when Entering into a Corporate Integrity Agreement Not long ago, Corporate Integrity
More informationTHE FRAUD PREVENTION SYSTEM IDENTIFIED MILLIONS IN MEDICARE SAVINGS, BUT THE DEPARTMENT COULD STRENGTHEN SAVINGS DATA
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL THE FRAUD PREVENTION SYSTEM IDENTIFIED MILLIONS IN MEDICARE SAVINGS, BUT THE DEPARTMENT COULD STRENGTHEN SAVINGS DATA BY IMPROVING ITS
More informationDeveloped by the Centers for Medicare & Medicaid Services
Developed by the Centers for Medicare & Medicaid Services Every year millions of dollars are improperly spent because of fraud, waste, and abuse. It affects everyone. Including YOU. This training will
More informationOctober 9, 2015. RIN 0906-AB08 340B Drug Pricing Program Omnibus Guidance. Dear Director Pedley:
October 9, 2015 Krista Pedley Director, Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane Mail Stop 08W05A Rockville, Maryland 20857 Re: RIN 0906-AB08 340B Drug
More informationChapter 9 UNDERSTANDING PRACTICE VALUATIONS. Seller's Perspective. Incoming Doctor's Perspective. Declining Practice Values
Chapter 9 UNDERSTANDING PRACTICE VALUATIONS The IRS has defined fair market value as the price at which property would change hands between a willing purchaser and a willing seller, neither being under
More informationBusiness Valuation. Presented by: CPA Assurance http://www.cpaassurance.com
Business Valuation Presented by: CPA Assurance http://www.cpaassurance.com Presentation Summary Overview of business valuation approaches Standards of value Valuation adjustments Current developments Using
More information2015-340B & Prime Vendor Program Update
2015-340B & Prime Vendor Program Update Christopher A. Hatwig, R.Ph., MS, FASHP President, Apexus 340B Sales by Entity Types Percentage of Total Apexus Participant Sales 90.00% 80.00% 70.00% 60.00% 50.00%
More informationHow to Determine Commercial Reasonableness of Hospital- Physician Compensation Arrangements
How to Determine Commercial Reasonableness of Hospital- Physician Compensation Arrangements AHLA Physicians Organizations Law Institute Phoenix, AZ February 11, 2013 Presenters: Marc Goldstone, Esq. Community
More information4/3/2015 WHAT IS 340B? DISCLOSURE. No conflicts of interest to disclose
WHAT IS 340B? S C O T T M I L N E R P H AR M D, M B A DISCLOSURE No conflicts of interest to disclose 1 OBJECTIVES At the end of this presentation we should be able to: Describe the origin of the 340b
More informationFederal 340B Drug Pricing Program
2015 CliftonLarsonAllen LLP Federal 340B Drug Pricing Program March 6, 2015 Continuous learning in action Learning Objectives Explain the intent of the Federal 340B Drug Pricing Program List the eligibility
More informationSpin-Off of Time Warner Cable Inc. Tax Information Statement As of March 19, 2009
Spin-Off of Time Warner Cable Inc. Tax Information Statement As of March 19, 2009 On March 12, 2009, Time Warner Inc. ( Time Warner ) completed the spin-off (the Spin-Off ) of Time Warner s ownership interest
More informationSTARK AND ANTI-KICKBACK PROTECTION FOR E-PRESCRIBING AND ELECTRONIC HEALTH RECORDS
STARK AND ANTI-KICKBACK PROTECTION FOR E-PRESCRIBING AND ELECTRONIC HEALTH RECORDS Andrew B. Wachler, Esq. Adrienne Dresevic, Esq. Wachler & Associates, P.C. Royal Oak, Michigan On October 11, 2005, in
More informationI n joining a public company board of directors, you
Corporate Law & Accountability Report Reproduced with permission from Corporate Accountability Report, 23 CARE, 2/4/16. Copyright 2016 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com
More informationOnce your account is established, you will receive a confirmation email or fax with your account number and an order form.
Welcome to sanofi-aventis U.S. LLC and Genzyme Corporation. This new account welcome kit provides you with essential information on how to request a new account and understand our standard business policies
More informationProfessional Qualifications of John T. Iacopi, CPA/ABV, CBA, CVA
Professional Qualifications of John T. Iacopi, CPA/ABV, CBA, CVA (Covering Business Appraisal, Consulting, Litigation Services Only) Prepared as of May 1, 2015 Educational Background, License and Certifications
More information340B Drug Pricing Program: Recent Developments and Compliance Update
340B Drug Pricing Program: Recent Developments and Compliance Update Elizabeth S. Elson, Esq. Anil Shankar, Esq. November 19, 2015 Attorney Advertising Prior results do not guarantee a similar outcome
More informationInstructions for Form 8283 (Rev. December 2014)
Instructions for Form 8283 (Rev. December 2014) Noncash Charitable Contributions Department of the Treasury Internal Revenue Service Section references are to the Internal Revenue Code unless otherwise
More informationGAO MEDICARE PART D COVERAGE GAP. Discount Program Effects and Brand-Name Drug Price Trends. Report to Congressional Requesters
GAO United States Government Accountability Office Report to Congressional Requesters September 2012 MEDICARE PART D COVERAGE GAP Discount Program Effects and Brand-Name Drug Price Trends To access this
More information